Company facts for investors, buyers, job seekers, and healthcare professionals
Find healthcare AI companies that fit the work you need done. Compare their products and ownership, then follow company news and evidence before deciding what to explore next.
Know What the Company Is, What Changed, and Where to Verify It
Each profile connects the company to its market category, ownership, stock name or public parent, careers, qualification signals, first-hand developments, evidence, and FDA records.
Brainomix said on 28 October 2026 that its AI imaging analysis of the Phase 3 CHARM trial identified what it calls promising treatment signals in severe stroke patients. The company says its reading of non-contrast CT scans may help identify patients more likely to benefit from treatment with CIRARA, and that the data were presented at the 18th World Stroke Conference in Seoul between 21 and 23 October 2026. The page on the Brainomix site is a short summary that links to a newswire release this desk could not open, so the figures, the number of patients, the comparison group and the authors are not available here. Brainomix states no regulatory status for this use of the software.
Why it matters: Everything in this one is the company talking about its own analysis, and that is how it should be read. A conference presentation is not a published paper, and a signal is not a result. What makes it worth noting anyway is the job the software is being given. Reading a plain CT scan to sort patients into likely responders is an attempt to rescue information from a trial, and that is a far more valuable use of imaging AI than flagging a scan for a radiologist, because it could change which patients a future trial enrols. It is also the use with the most room for a wrong answer, since a model that sorts patients after the fact can find a pattern that does not repeat. Promising treatment signals carries no number, and until the full analysis is public nobody outside can judge it.
Commure said on 20 October 2026 that Commure Autonomous Coding had achieved Epic Toolbox designation for fully autonomous coding. The announcement describes the Toolbox designation as marking vendors that follow Epic's recommended Blueprint and integration practices, which it says streamlines integration and security review and lets coders check codes inside their existing Epic system. Commure says the product recommends ICD-10, CPT and E&M codes and modifiers with a written rationale, covering the step from a clinician's note through claim creation. The announcement reports that at Ob Hospitalist Group, described as the nation's largest OB/GYN provider group, clinicians cut charge entry time by 83 percent within three months and the software coded more than 85 percent of all charges. Tanay Tandon, Commure's chief executive, is quoted saying healthcare spends more than 250 billion dollars a year on administrative work that produces no clinical value.
Why it matters: Toolbox designation is an integration and process credential, not a measure of coding accuracy. It matters because it removes a real obstacle: coders reviewing AI output in a second application is where a lot of autonomous coding pilots quietly die. The customer figures are the part worth pressing on. An 83 percent cut in charge entry time is a measure of clinician effort, and 85 percent of charges coded is a measure of how much work the software took on, but neither one tells you whether the codes were right or whether denials went up or down. A revenue cycle leader should ask for the accuracy and denial numbers beside these two before treating the result as a win, and should note that an obstetrics hospitalist group has a narrower range of cases than a general hospital.
Abridge published an interview on 18 October 2026 with Dr Jessica Faraci, a family medicine physician at MaineHealth, about her use of Abridge Assistant. She says the tool saves her about 30 minutes a day and that medical history letters now take three to five minutes to finish. The piece also names Abridge products it calls Assistant for Clinicians, the Assistant Prompt Library and Care Signals, and cites a Sutter Health case study in which 78 percent of clinicians reported improved work satisfaction. It is an Abridge blog interview rather than a study, and it reports the experience of one physician.
Why it matters: One named doctor describing her own day is worth more than it looks, because she can be asked about it later and a vendor average cannot. Thirty minutes a day is also a believable number rather than an impressive one, which is a point in its favour. What it is not is evidence. One family medicine physician at one health system tells you nothing about how the tool behaves in a busy emergency department or on a complicated specialty visit, and nobody reports whether the notes and letters were accurate. The Sutter Health figure is about how clinicians felt, and satisfaction can rise while note quality falls. Read this as a reference call that happens to be published.
Philips said on 14 October 2026 that it had reached 1,000 global installations of SmartSpeed Precise, its AI-based MRI image reconstruction software. The company says the software is used in at least 95 percent of compatible clinical scanning on the systems where it is installed. Its stated performance claims are that SmartSpeed Precise delivers images up to 80 percent sharper and lets scans be completed up to three times faster compared with Philips SENSE imaging, that it can save an average of 215 hours of scanning time per system per year, and that this represents capacity for roughly 624 additional MRI examinations per system each year, or about 215,000 hours and more than 624,000 additional examinations across all 1,000 systems. Ioannis Panagiotelis, business leader for MRI at Philips, is quoted saying faster is only meaningful when it comes with the image quality clinicians need.
Why it matters: The adoption figure is the useful part of this announcement. Plenty of imaging AI gets bought, installed and then left switched off because it slows the technologist down or the radiologists do not trust the output, so a vendor claiming the software runs on nearly every eligible scan is making a claim it can be checked on. The time figures need more care. The 215 hours and the 624 extra examinations are Philips arithmetic built on its own comparison against its older SENSE method, not an independent measurement, and extra scanner capacity only turns into extra examinations if a department also has the staff and the referrals to fill it. Nothing here is a clinical claim, and faster scans with sharper pictures do not by themselves mean a better diagnosis.
One Company Profile, the Facts Around It
A company name alone does not tell you what you can buy, whether the stock is direct exposure, what jobs require, or which claims hold up. AI Healthcare Now connects those questions so you can move from an announcement to the company, market, evidence, regulation, and career facts behind it.
Some healthcare AI companies have their own listed shares. Others belong to public parents or remain private; this guide separates those relationships.
An AI governance framework for a hospital is not a policy document. It is a standing decision process that says who approves an AI tool, what evidence they require, who owns it after go-live, and what triggers turning it off. Most of what gets published as a framework skips the last two.
There is no AI compliance regime in United States healthcare. There are existing obligations that AI tools fall inside, and the compliance work is figuring out which ones apply to which tool. That reframing removes most of the confusion and all of the waiting.
Responsible AI claims become useful when a hospital can verify who was studied, what the clinician sees, who owns failures, and what gets measured after launch.
Get research notes, vendor category updates, patient discovery trends, and healthcare AI strategy briefings.
Related Properties
AI Healthcare Now connects the healthcare AI conversation to a wider network of specialized healthcare, aging, longevity, and medical marketing properties.
